• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钾通道开放剂的构效关系

Structure-activity relationships of K+ channel openers.

作者信息

Edwards G, Weston A H

机构信息

Department of Physiological Sciences, University of Manchester, UK.

出版信息

Trends Pharmacol Sci. 1990 Oct;11(10):417-22. doi: 10.1016/0165-6147(90)90149-3.

DOI:10.1016/0165-6147(90)90149-3
PMID:2256183
Abstract

Seven groups of synthetic agent, distinguished by a combination of their chemical and pharmacological characteristics exert some or all of their effects by opening plasmalemmal K+ channels primarily in smooth muscle. Progress over the past two years now allows broad structure-activity relationships to be formulated within many of the individual groups of agent. Gillian Edwards and Arthur Weston review the historical basis of these discoveries and comment on the significance of new developments. They focus on the search for tissue and channel selectivity, two factors likely to be important for the successful clinical deployment of these substances as antihypertensive and bronchodilator agents.

摘要

七组合成剂,根据其化学和药理学特性的组合加以区分,主要通过打开平滑肌中的质膜钾通道发挥部分或全部作用。过去两年的研究进展使得现在能够在许多单个剂组内制定广泛的构效关系。吉莉安·爱德华兹和亚瑟·韦斯顿回顾了这些发现的历史基础,并对新进展的意义进行了评论。他们专注于寻找组织和通道选择性,这两个因素对于将这些物质成功临床用作抗高血压和支气管扩张剂可能很重要。

相似文献

1
Structure-activity relationships of K+ channel openers.钾通道开放剂的构效关系
Trends Pharmacol Sci. 1990 Oct;11(10):417-22. doi: 10.1016/0165-6147(90)90149-3.
2
Recent progress in potassium channel opener pharmacology.
Biochem Pharmacol. 1992 Jan 9;43(1):47-54. doi: 10.1016/0006-2952(92)90659-7.
3
Potassium channel openers as potential therapeutic weapons in ion channel disease.钾通道开放剂作为离子通道疾病的潜在治疗手段。
Kidney Int. 2000 Mar;57(3):838-45. doi: 10.1046/j.1523-1755.2000.00923.x.
4
Latest developments in K-channel modulator pharmacology.
Z Kardiol. 1991;80 Suppl 7:1-8.
5
Is there a therapeutic future for "potassium channel openers'?“钾通道开放剂”是否具有治疗前景?
Clin Sci (Lond). 1996 Dec;91(6):651-63. doi: 10.1042/cs0910651.
6
Current trends in the study of potassium channel openers.
Gen Pharmacol. 1993 Mar;24(2):275-81. doi: 10.1016/0306-3623(93)90303-f.
7
Potassium channel openers and other regulators of KATP channels.钾通道开放剂及其他KATP通道调节剂。
Clin Exp Pharmacol Physiol. 1994 Aug;21(8):583-97. doi: 10.1111/j.1440-1681.1994.tb02559.x.
8
K(+)-channel openers: new antihypertensive drugs?
Clin Physiol Biochem. 1990;8 Suppl 2:46-56.
9
KATP channel openers: structure-activity relationships and therapeutic potential.ATP敏感性钾通道开放剂:构效关系与治疗潜力。
Med Res Rev. 2004 Mar;24(2):213-66. doi: 10.1002/med.10060.
10
Recent developments in the chemistry of potassium channel activators: the cromakalim analogs.
Curr Med Chem. 2004 May;11(9):1213-22. doi: 10.2174/0929867043365378.

引用本文的文献

1
KATP Channels in the Cardiovascular System.心血管系统中的钾离子通道。
Physiol Rev. 2016 Jan;96(1):177-252. doi: 10.1152/physrev.00003.2015.
2
Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.新型二氢吡啶钾通道开放剂A-312110与重组磺酰脲受体及KATP通道的相互作用:与氰基胍P1075的比较
Br J Pharmacol. 2004 Apr;141(7):1098-105. doi: 10.1038/sj.bjp.0705718. Epub 2004 Mar 15.
3
Treatment with low-dose diazoxide in two growth-retarded prepubertal girls with glycogen storage disease type Ia resulted in catch-up growth.
在两名患有Ia型糖原贮积病的青春期前生长迟缓女孩中,使用低剂量二氮嗪治疗导致了追赶性生长。
J Inherit Metab Dis. 1997 Nov;20(6):790-8. doi: 10.1023/a:1005319818015.
4
ATP-regulated K+ channel in mitochondria: pharmacology and function.线粒体中ATP调节的钾通道:药理学与功能
J Bioenerg Biomembr. 1996 Apr;28(2):147-52. doi: 10.1007/BF02110645.
5
Potassium channel agonists modify the local anaesthetic activity of bupivacaine in mice.钾通道激动剂可改变布比卡因在小鼠体内的局部麻醉活性。
Can J Anaesth. 1996 Aug;43(8):871-6. doi: 10.1007/BF03013042.
6
Effects of P1060 and aprikalim on whole-cell currents in rat portal vein; inhibition by glibenclamide and phentolamine.P1060和阿普卡林对大鼠门静脉全细胞电流的影响;格列本脲和酚妥拉明的抑制作用。
Br J Pharmacol. 1993 Apr;108(4):991-8. doi: 10.1111/j.1476-5381.1993.tb13496.x.
7
A target K+ channel for the LP-805-induced hyperpolarization in smooth muscle cells of the rabbit portal vein.LP-805诱导兔门静脉平滑肌细胞超极化的靶钾通道。
Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):329-35. doi: 10.1007/BF00167453.
8
ATP-modulated K+ channels sensitive to antidiabetic sulfonylureas are present in adenohypophysis and are involved in growth hormone release.对降糖磺脲类药物敏感的ATP调节钾通道存在于腺垂体中,并参与生长激素的释放。
Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1340-4. doi: 10.1073/pnas.90.4.1340.
9
K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus.钾离子通道开放剂可防止大鼠海马体中因全脑缺血诱导的c-fos、c-jun、热休克蛋白和淀粉样β蛋白前体基因的表达以及神经元死亡。
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9431-5. doi: 10.1073/pnas.90.20.9431.
10
Comparison of in vitro effects of cicletanine, its enantiomers and major metabolite on rat thoracic aorta.西氯他宁及其对映体和主要代谢产物对大鼠胸主动脉的体外作用比较。
Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):548-52. doi: 10.1007/BF00166749.